Earlier this week, AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for the treatment of obesity, from Danish research ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of $240.00. The company’s shares closed yesterday at ...

AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the terms of the agreement, AbbVie will lead development ...

AbbVie’s Allergan Aesthetics division has a presence in targeted fat reduction with CoolSculpting, a nonsurgical medical device. The company does not market this offering as a treatment for ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. President Donald Trump’s first month in office has been dizzying for U.S ...

We recently published a list of 10 Best DRIP Stocks To Own Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best DRIP stocks to own now.

Ford has used some version of its famous script logo for more than a century, but despite its widespread usage, people are scratching their heads over a detail they just noticed. In a viral TikTok ...

The year began with the expectation that Pfizer and Allergan would join to become the world’s largest ... into separate generics and innovative product companies. Meanwhile, AbbVie and Ireland-based ...

Since the publication of my article "Top 4 Immunology Stocks Poised For Growth In 2025," AbbVie's stock price (NYSE:ABBV) has risen by over 17%. The first reason is that the North Chicago-based ...